RxDoctor Payments Data

Jason Bradley, MD

Interventional Cardiology · Lubbock, TXNPI 1073677977

Payments from drug & device makers

$68,219in general payments, 2019–2025

Across 758 payments — averaging $90.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$18K
  • Novartis$12K
  • Cardinal Health 200 LLC$9K
  • Pfizer$7K
  • Boston Scientific$6K
  • Avinger Inc.$3K
  • plus $14K from 43 others

What the payments were for

  • Consulting fees$8,66313%
  • Speaking & faculty fees$40,01559%
  • Travel & lodging$4,3726%
  • Food & beverage$15,15622%
  • Education$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$68,219 in reported general payments places this provider in the 80th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$2,541,413
Medicare patients
2,449
Services billed
24,523

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,391$1,536,134
EntrestoSacubitril/Valsartan343$431,432
XareltoRivaroxaban391$400,625
Repatha SureclickEvolocumab408$283,274
FarxigaDapagliflozin Propanediol112$111,393
MultaqDronedarone Hcl71$97,113
Praluent PenAlirocumab97$46,218
Metoprolol Succinate1,959$30,785
BrilintaTicagrelor30$27,451
ClopidogrelClopidogrel Bisulfate2,023$23,756
Nitro-DurNitroglycerin13$20,334
Ranolazine ErRanolazine240$20,191
VascepaIcosapent Ethyl21$19,543
Repatha SyringeEvolocumab19$19,483
Potassium Chloride806$17,118

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$6,671$1,536,1341,391 claims
NovartisEntresto$11,634$431,432343 claims
Johnson & JohnsonXarelto$434$400,625391 claims
AstraZenecaFarxiga, Brilinta$18,018$138,843142 claims
Sanofi-aventis U.S. LLCMultaq$170$97,11371 claims
Boehringer IngelheimJardiance$209$14,47216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →